{"title":"更正为 沉默 PCMT1 可通过 PI3K/Akt/STMN1 途径提高乳腺癌细胞对紫杉醇的敏感性。","authors":"","doi":"10.1111/cbdd.14577","DOIUrl":null,"url":null,"abstract":"<p>Zhang K, Li JY, Li K. Silencing PCMT1 enhances the sensitivity of breast cancer cells to paclitaxel through the PI3K/Akt/STMN1 pathway. <i>Chem Biol Drug Des</i>. 2024 Jun;103(6):e14559. doi: 10.1111/cbdd.14559. PMID: 38853025.</p><p>In page 1 of Author Information section, the text “Correspondence Kai Li, Department of Oncology, Renmin Hospital, Hubei University of Medicine, Shiyan 442000, Hubei, China. Email: <span>[email protected]</span>” was incorrect. This should have read: “Correspondence Kai Li, Department of Pathology, Renmin Hospital, Hubei University of Medicine, Shiyan 442000, Hubei, China. Email: <span>[email protected]</span>.”</p><p>We apologize for this error.</p>","PeriodicalId":143,"journal":{"name":"Chemical Biology & Drug Design","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cbdd.14577","citationCount":"0","resultStr":"{\"title\":\"Correction to Silencing PCMT1 enhances the sensitivity of breast cancer cells to paclitaxel through the PI3K/Akt/STMN1 pathway\",\"authors\":\"\",\"doi\":\"10.1111/cbdd.14577\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Zhang K, Li JY, Li K. Silencing PCMT1 enhances the sensitivity of breast cancer cells to paclitaxel through the PI3K/Akt/STMN1 pathway. <i>Chem Biol Drug Des</i>. 2024 Jun;103(6):e14559. doi: 10.1111/cbdd.14559. PMID: 38853025.</p><p>In page 1 of Author Information section, the text “Correspondence Kai Li, Department of Oncology, Renmin Hospital, Hubei University of Medicine, Shiyan 442000, Hubei, China. Email: <span>[email protected]</span>” was incorrect. This should have read: “Correspondence Kai Li, Department of Pathology, Renmin Hospital, Hubei University of Medicine, Shiyan 442000, Hubei, China. Email: <span>[email protected]</span>.”</p><p>We apologize for this error.</p>\",\"PeriodicalId\":143,\"journal\":{\"name\":\"Chemical Biology & Drug Design\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2024-07-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cbdd.14577\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Chemical Biology & Drug Design\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/cbdd.14577\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chemical Biology & Drug Design","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cbdd.14577","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
Zhang K, Li JY, Li K. Silencing PCMT1 enhanced the sensitivity of breast cancer cells to paclitaxel through the PI3K/Akt/STMN1 pathway.Chem Biol Drug Des.2024 Jun;103(6):e14559. Doi: 10.1111/cbdd.14559.PMID：38853025.第1页 "作者信息 "中的 "通讯作者：湖北十堰442000 湖北医药学院附属人民医院肿瘤科 李凯"。电子邮箱：[email protected]"有误：[email protected]"有误。应改为"Correspondence Kai Li, Department of Pathology, Renmin Hospital, Hubei University of Medicine, Shiyan 442000, Hubei, China.电子邮箱：[email protected]：[email protected]。"我们对此错误深表歉意。
Correction to Silencing PCMT1 enhances the sensitivity of breast cancer cells to paclitaxel through the PI3K/Akt/STMN1 pathway
Zhang K, Li JY, Li K. Silencing PCMT1 enhances the sensitivity of breast cancer cells to paclitaxel through the PI3K/Akt/STMN1 pathway. Chem Biol Drug Des. 2024 Jun;103(6):e14559. doi: 10.1111/cbdd.14559. PMID: 38853025.
In page 1 of Author Information section, the text “Correspondence Kai Li, Department of Oncology, Renmin Hospital, Hubei University of Medicine, Shiyan 442000, Hubei, China. Email: [email protected]” was incorrect. This should have read: “Correspondence Kai Li, Department of Pathology, Renmin Hospital, Hubei University of Medicine, Shiyan 442000, Hubei, China. Email: [email protected].”
期刊介绍：
Chemical Biology & Drug Design is a peer-reviewed scientific journal that is dedicated to the advancement of innovative science, technology and medicine with a focus on the multidisciplinary fields of chemical biology and drug design. It is the aim of Chemical Biology & Drug Design to capture significant research and drug discovery that highlights new concepts, insight and new findings within the scope of chemical biology and drug design.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
